Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
PLANO, Texas, May 03, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 18th Annual B. Riley Co. Investor Conference in Santa Monica, CA. Management will also be available for one-on-one meetings at the conference.
Event: 18th Annual B. Riley Co. Investor Conference
Format: Presentation and One-on-One Meetings
Date: Wednesday, May 24, 2017
Time: 2:00 pm PT
A webcast of the Company’s presentation will be available on the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the chat will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
